AstraZeneca Stops Lung Cancer Trial
AstraZeneca has discontinued its clinical trial of experimental drug volrustomig after determining it failed to outperform existing lung cancer treatments. However, the company reported positive results from two separate late-stage trials that bolster its cancer portfolio, particularly one combining Tagrisso with Orpathys for non-small cell lung cancer patients.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- BloombergTrace: Center
AstraZeneca Reports Mixed Lung Cancer Trial Results
AstraZeneca has discontinued its clinical trial of experimental drug volrustomig after determining it failed to outperform existing lung cancer treatments. However, the company reported positive results from two separate late-stage trials that bolster its cancer portfolio, particularly one combining Tagrisso with Orpathys for non-small cell lung cancer patients.
Rate outletRead original
Readers say
How does this story lean?
Outlet ratings above are Trace's curated source map. Vote here (same as on the home feed) — one vote per browser, changeable anytime. Rate individual outlets in the coverage list below.
Comments
0No comments yet. Say what you noticed in the coverage.
Trending